Immunotherapy duo shows promise against advanced oral cancer
NCT ID NCT05681039
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 29 times
Summary
This study tests whether giving two immunotherapy drugs (tiragolumab and atezolizumab) before and after standard surgery and chemoradiation can help control advanced oral cancer. It includes 29 adults with newly diagnosed, stage 3-4 oral cavity squamous cell carcinoma that has a specific protein (PD-L1). The main goal is to see how many patients have a major reduction in tumor cells after the drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.